Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares fell 4% during mid-day trading on Wednesday . The stock traded as low as $41.13 and last traded at $41.28, with a volume of 280,270 shares trading hands. The stock had previously closed at $43.00.

Several brokerages have issued reports on ITCI. Cowen and Company restated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, June 29th. Leerink Swann reaffirmed a “buy” rating on shares of Intra-Cellular Therapies in a research note on Saturday, April 30th. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Tuesday, May 17th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $57.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $70.78.

The firm’s market capitalization is $1.78 billion. The company has a 50-day moving average price of $39.74 and a 200 day moving average price of $34.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.08. During the same period last year, the company earned ($0.61) EPS. The firm earned $0.23 million during the quarter, compared to analysts’ expectations of $0.02 million. The business’s quarterly revenue was up 283.3% on a year-over-year basis. On average, analysts forecast that Intra-Cellular Therapies Inc. will post ($3.17) EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of ITCI. BlackRock Advisors LLC boosted its stake in Intra-Cellular Therapies by 1.7% in the fourth quarter. BlackRock Advisors LLC now owns 1,199,043 shares of the biopharmaceutical company’s stock valued at $64,497,000 after buying an additional 19,938 shares during the period. Jennison Associates LLC boosted its position in Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock worth $67,660,000 after buying an additional 855,846 shares during the last quarter. Marshall Wace LLP boosted its position in Intra-Cellular Therapies by 23.5% in the fourth quarter. Marshall Wace LLP now owns 23,148 shares of the biopharmaceutical company’s stock worth $1,245,000 after buying an additional 4,410 shares during the last quarter. New York State Common Retirement Fund boosted its position in Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock worth $1,431,000 after buying an additional 5,800 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock worth $4,233,000 after buying an additional 65,700 shares during the last quarter.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.